Coronavirus, the doctor from Naples who first tested the anti-arthritis drug: "I remain cautious, but the data is welcoming"
The Italian Medicines Agency has authorized a study to evaluate the effectiveness of tocilizumab. Oncologist Paolo Ascierto: "Not all patients’ response experimentation will clarify who to focus on" ROME. It's not the vaccine, of course. But for those affected by coronavirus it is a hope of cure. With a decision taken in record time, the Italian Medicines Agency (AIFA) announced Tuesday evening that it had authorized the Tocivid-19 study which will evaluate the efficacy and safety of tocilizumab - an immunosuppressant used for rheumatoid arthritis - in the treatment of pneumonia caused by the new coronavirus. The study is promoted by the National Institute for the Study and Treatment of Cancer in Naples with the University of Modena and Reggio Emilia and the IRCCS of Reggio Emilia, and with the Aifa Technical Scientific Commission. Coronavirus, how to dialogue with adolescent children in quarantine between frustration and anger: the psychologist's answers